Navigation Links
Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
Date:9/23/2011

CHICAGO, Sept. 23, 2011 /PRNewswire/ -- Today, Zacks Equity Research discusses the Pharmaceuticals, including Vertex Pharma (Nasdaq: VRTX), AstraZeneca (NYSE: AZN), Abbott Labs (NYSE: ABT), Allergan (NYSE: AGN) and Onyx Pharmaceuticals (Nasdaq: ONXX).

(Logo:  http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

A synopsis of today's Industry Outlook is presented below. The full article can be read at http://www.zacks.com/stock/news/61553/Pharmaceuticals+Stock+Outlook+-+Sept.+2011

Emerging markets are slowly and steadily gaining in importance, and several companies are now shifting their focus to these areas. Emerging markets should see strong sales thanks to increased demand for medicines. Several factors like government initiatives for healthcare, new patient population, and increasing use of generics should help drive demand. Growth in emerging markets could help stabilize the base business during the industry's 2010-15 patent cliff.

According to the IMS Institute, spending on medicines in emerging markets will double to $285-$315 billion in the next five years from $151 billion in 2010, driven by strong economic growth coupled with endeavors of concerned governments to expand access to healthcare. This will catapult "pharmerging" markets to the second position by 2015 where spending on medicines is concerned.

Branded Drugs Market Share to Decline

According to the IMS Institute, market share for branded drugs will continue declining over the next five years. Branded drugs market share, which declined from 70% in 2005 to 64% in 2010, is expected to decline to 53% by 2015. The decline will be driven by patent expiries, with generics accounting for a significant part of pharma spending. Spending on branded medicines in 2015 is expected to remain at the same level as in 2010.

OPPORTUNITIES

We currently have a Neutral outlook on large-cap pharma stocks (Zacks #3 Rank). While the companies will continue to face challenges like pricing pressure and genericization, growth in emerging markets and product approvals could help reduce the impact.

According to the IMS Institute, 44 new branded products were launched in 2010. However, the new product approval mix was more towards orphan drugs and medicines with the same mechanism of action as existing therapies.

Important product approvals in 2011 so far include the approval of Johnson & Johnson's prostate cancer therapy, Zytiga, Merck's hepatitis C virus (HCV) treatment, Victrelis, Bristol-Myers Squibb's  melanoma treatment, Yervoy, and kidney transplant therapy Nulojix, Vertex Pharma's (Nasdaq: VRTX) HCV treatment, Incivek and AstraZeneca's (NYSE: AZN) blood thinner Brilinta, among others.

We currently have Neutral recommendations on companies like Abbott Labs (NYSE: ABT), Johnson & Johnson, Allergan (NYSE: AGN) and Pfizer. We believe that Allergan's presence across different segments and geographies will help maintain decent growth going forward.

In spite of the Neutral stance on the stock, we are positive on Bristol-Myers. Earnings estimates have been upped by majority of the analysts covering the stock after its strong second quarter results. 2011 has been a fruitful year for Bristol-Myers so far, with many key drugs getting approved. Growth in the coming quarters is expected to be driven by new product launches and acquisitions and deals.

WEAKNESSES

We recommend avoiding names that offer little growth or opportunity for a take-out. These include companies which are developing drugs that are likely to face regulatory hurdles. The US Food and Drug Administration (FDA) has been exercising more caution in granting approval to new products and several candidates are facing delays in receiving final approval.

We advise investors to avoid names such as Onyx Pharmaceuticals (Nasdaq: ONXX) on which we have an Underperform recommendation. The company delivered lackluster results in the second quarter of 2011 due to lower revenues and higher operating expenses.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4581.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter:  http://twitter.com/zacksresearch

Join us on Facebook:  http://www.facebook.com/ZacksInvestmentResearch

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com


'/>"/>
SOURCE Zacks Investment Research, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Rates CardioGenics Outperform With Six-Month Target of $1.22
2. Zacks Investment Research Initiates Coverage on Viral Genetics
3. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
4. U.S. Meat Industry Will Respond to World Cancer Research Fund Report
5. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
8. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
9. Industry Executives Finding Value in Shift of Scientific Publications
10. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  AfterPill.com is reporting that this week,s ... for all women who are at risk of unintended ... year and raises the risks of unprotected sex in ... According to the Guttmacher Institute, there are 43 ... child-bearing age, who have sex without the intention of ...
(Date:2/11/2016)... de fevereiro de 2016  A Proliant Biologicals ... de soroalbumina bovina (BSA -- Bovine Serum ... na Ilha Norte da Nova Zelândia, em Feilding. ... na fábrica da Proliant nos EUA, localizada em ... e instalação dos equipamentos foram feitos de forma ...
(Date:2/11/2016)... MEADOWS , Ill. and INDIANAPOLIS , ... milestone for many young people, but for those with ... Not only do these students juggle class schedules, assignments ... of living with type 1 diabetes. On top of ... first time. Diabetes Scholars Foundation (Foundation) ...
Breaking Medicine Technology:
(Date:2/11/2016)... Alpharetta, Georgia (PRWEB) , ... February 11, 2016 ... ... Physicians Group (DMPG) will use the action analytics leader’s population health solutions, ... analytics and clinical support to the Atlanta-area healthcare system. Details of the contract ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s ... of cosmetic procedures. Along with performing procedures, the magazine also highlights that Dr. ... cosmetic procedures. One of the most common procedures he performs is his natural ...
(Date:2/11/2016)... ... 2016 , ... Image One USA veteran franchise owner Maria Bogacki ... buildings of Nashville that will benefit. , “I’ve enjoyed being a part of the ... was no question that I would bring my business with me,” Bogacki said. “The ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... to reverse diabetes has been gearing up for their simultaneous grand openings in ... It’s about right now that you’re probably wondering, is reversing diabetes possible? According ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a new paper ... surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore the importance ... for rhinoplasty surgeons when addressing this vital area. , The upper lateral cartilage ...
Breaking Medicine News(10 mins):